Biopolis — Singapore's Biomedical R&D Cluster

Biopolis is an 18.5-hectare biomedical R&D cluster within Singapore's one-north precinct, opened in October 2003 after a S$500 million government investment (built in under 20 months). It was created as the physical centrepiece of Singapore's strategy to build biomedical sciences as its fourth economic pillar, and expanded across six phases to over 3.5 million sq ft by 2022.

The knowledge-transfer model rests on deliberate co-location: five A*STAR research institutes — the Genome Institute of Singapore (GIS), Institute of Bioengineering and Nanotechnology (IBN), Bioinformatics Institute (BII), Institute of Molecular and Cell Biology (IMCB), and Bioprocessing Technology Institute — share campus buildings with private tenants including Novartis (USD 200 M over five years), GlaxoSmithKline, and Procter & Gamble (USD 250 M innovation centre). The Novartis Institute for Tropical Diseases, set up as a public-private partnership with Singapore's EDB in 2002, is the flagship example of this model.

Measured outcomes — BioSpace/PMC sources for 2012; EDB Singapore for 2023: biomedical manufacturing output grew nearly fivefold from SGD 6 B to SGD 29.4 B; value-added reached SGD 15.3 B (25.5% of total manufacturing value); employment grew 2.5× from 6,000 to 15,700 by 2012 and reached 26,481 in biopharmaceutical manufacturing alone by 2023; the sector's manufacturing output reached SGD 39 B by 2023. 25% of all biotechs currently operating in Singapore are A*STAR spinoffs.

Cautionary note: spin-off commercialisation has been slower than anticipated — academic reviews note only a handful of novel diagnostics discovered at Biopolis have reached market, and the cluster has historically depended on internationally recruited scientists rather than home-grown talent.

Read the full analysis: https://www.a-star.edu.sg/bmrc